The combined treatment of necroptosis inhibitor Necrostatin-1 and apoptosis inhibitor zVAD led to reduced infarct size and a greater involvement of the RIPK1-mediated necroptosis pathway was demonstrated.61 In addition, RIPK3-deficient mice were strongly protected in a model of myocardial infarction.5 In a mouse model of cardiac IRI,62 Necrostatin-1 administration reduced infarct size, inhibited RIPK1/RIPK3 phosphorylation, and significantly reduced cell death. Here, RIPK1 is linked to myocardial infarction.